All right, now I'm gonna pass it over to Lauren to talk a little bit about the data so we can really see how these medications performed in clinical trials.

Good morning.

I'm going to go ahead and apologize because I'm a little under the weather.

So not only do you have to listen to my southern accent, but you have to listen to a a very deep southern accent this morning, so I apologize for that, but we have now looked at how TIK2 inhibitors are mechanistically different from the broader suppression that we see in JAK inhibitors, but I think really the most important thing is the data, so efficacy and safety, because you can have a really pretty MOA diagram, but it doesn't help us if it doesn't correlate to better outcomes.

Let's get into some of the data.

How many of you in the room have prescribed Ducravacitinib? Okay, not as many as I was hoping.

So, Ducravacitinib was the first and it's still currently the only FDA approved selective TIK2 inhibitor.

So what do you guys think? What should we be thinking about for her in terms of what therapy to pick?